Pathophysiology and treatment of pulmonary arterial hypertension

被引:0
|
作者
Humbert, M. [1 ,2 ,3 ]
Boucly, A. [1 ,2 ,3 ]
Guignabert, C. [1 ,2 ]
Savale, L. [1 ,2 ,3 ]
Sitbon, O. [1 ,2 ,3 ]
机构
[1] Univ Paris Saclay, Fac Med, F-94270 Le Kremlin Bicetre, France
[2] Inserm, UMR S 999, F-94270 Le Kremlin Bicetre, France
[3] Hop Bicetre, AP HP, Serv Pneumol, F-94270 Le Kremlin Bicetre, France
来源
关键词
Hypertension; Pulmonary; physiopathology; Vascular remodeling; DOUBLE-BLIND; PROSTACYCLIN ANALOG; THERAPY; TREPROSTINIL; AMBRISENTAN;
D O I
10.1016/j.banm.2022.10.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary arterial hypertension is a rare, complex and multifactorial disease in which pulmonary vascular remodelling plays a major role leading to right-heart failure and ultimately death. Pulmonary arterial hypertension therapies mainly target the vasoconstric-tion/vasodilatation balance and are not curative. Lung transplantation should be considered in patients refractory to these therapies. Novel therapies targeting the molecular basis of pul-monary vascular remodelling are in development. Regularly updated international guidelines allow best standard of care of these patients. (c) 2022 l'Academie nationale de medecine. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] The role of miR-146a in the pathophysiology of pulmonary arterial hypertension
    Gomes, Joana
    Ferreira, Pedro
    Adao, Rui
    Rocha, Carolina
    Vasconcelos, Ines
    Moreira, Adelino
    Silva, Carmen
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [32] The cellular basis of the pathophysiology and treatment of pulmonary hypertension
    Rich, S
    VASCULAR ENDOTHELIUM: RESPONSES TO INJURY, 1996, 281 : 175 - 180
  • [33] Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension
    Otani, Naoyuki
    Watanabe, Ryo
    Tomoe, Takashi
    Toyoda, Shigeru
    Yasu, Takanori
    Nakamoto, Takaaki
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [34] Current perspectives on the pathophysiology and treatment of pulmonary hypertension
    Bruch, L
    Parsi, A
    Kleber, FX
    HERZ, 2002, 27 (03) : 281 - 286
  • [35] Exercise pathophysiology differs between connective tissue diseases-associated pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension
    Zhang, Y.
    Jin, Q.
    Zhao, Z.
    Zhao, Q.
    Yu, X.
    Yan, L.
    Li, X.
    An, C.
    Ma, X.
    Xiong, C.
    Luo, Q.
    Liu, Z.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : 1063 - 1070
  • [36] Selexipag for the treatment of pulmonary arterial hypertension
    Genecand, Leon
    Wacker, Julie
    Beghetti, Maurice
    Lador, Frederic
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (05) : 583 - 595
  • [37] Bosentan for the treatment of pulmonary arterial hypertension
    Kenyon, KW
    Nappi, JM
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (7-8) : 1055 - 1062
  • [38] Pulmonary arterial hypertension: diagnosis and treatment
    Sadowski, Marcin
    Janion-Sadowska, Agnieszka
    Letek, Agnieszka
    Raczynski, Grzegorz
    Zandecki, Lukasz
    MEDICAL STUDIES-STUDIA MEDYCZNE, 2013, 29 (03) : 273 - 279
  • [39] Macitentan for the Treatment of Pulmonary Arterial Hypertension
    Hong, Irene S.
    Coe, Holly V.
    Catanzaro, Linda M.
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (04) : 538 - 547
  • [40] Epidemiology and treatment of pulmonary arterial hypertension
    Lau, Edmund M. T.
    Giannoulatou, Eleni
    Celermajer, David S.
    Humbert, Marc
    NATURE REVIEWS CARDIOLOGY, 2017, 14 (10) : 603 - 614